Latest news with #MitchellKapoor
Business Insider
23-07-2025
- Business
- Business Insider
Wainwright Analyst Slaps $0 Price Target on Sarepta Stock (SRPT)
Sarepta Therapeutics (SRPT) is under mounting Wall Street scrutiny amid safety concerns surrounding its flagship gene therapy, Elevidys. In a striking call, analyst Mitchell Kapoor at H.C. Wainwright assigned a $0 price target to SRPT stock, citing the tension between the company and the FDA (Food and Drug Administration). Meanwhile, Kapoor maintained his Sell rating on SRPT stock. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. SRPT stock has plunged more than 30% over the past five trading days, following Friday's news that the FDA requested Sarepta halt all shipments of Elevidys. In response, the company announced a voluntary pause in U.S. shipments of the therapy. For context, Elevidys is a one-time gene therapy from Sarepta that treats Duchenne muscular dystrophy (DMD) in patients aged four and up. HC Wainwright Sees FDA Clash as 'Unwinnable' Kapoor's rare price target cut comes after Sarepta initially refused to voluntarily pause Elevidys shipments, despite an FDA request following three patient deaths linked to the treatment. Additionally, Kapoor called the conflict with the FDA 'unwinnable' and warned that regulators are likely to force Elevidys off the market. A potential withdrawal could wipe out the therapy's revenue stream, leaving Sarepta stock effectively worthless. He also cautioned investors against single-product biotech companies, warning that such a business model may not be sustainable. Other Analysts Weigh In on SRPT Stock After Friday's decline, more than six analysts have downgraded their ratings on Sarepta stock. Notably, both Deutsche Bank Securities and Needham & Co. issued Sell ratings. Needham's analyst Gil Blum believes the ongoing 'showdown' between the FDA and Sarepta will likely end with formal regulatory action against Elevidys. He also warns that a potential market withdrawal could jeopardize Sarepta's ability to meet its $1.15 billion debt obligations due in 2027. On the other hand, J.P. Morgan's analyst Anupam Rama reiterated his Buy rating on SRPT stock, predicting an upside of over 50%. Rama believes Elevidys will likely remain available for ambulatory patients, as no deaths have been reported in that subgroup to date. These patients can walk independently or with minimal support. What is SRPT's Stock Price Forecast? According to TipRanks, Wall Street has a Hold consensus rating on SRPT stock, based on six Buys, 17 Holds, and three Sells assigned in the last three months. The average Sarepta Therapeutics stock price target of $30.82 implies a 131.4% upside potential.
Time of India
22-07-2025
- Business
- Time of India
Sarepta shares fall 7% after gene therapy maker pauses Elevidys shipments in US
Shares of Sarepta Therapeutics fell nearly 7% on Tuesday after the company agreed to comply with the U.S. health regulator's request to pause all shipments of its gene therapy Elevidys in the United States. The U.S. Food and Drug Administration on Friday asked Sarepta to voluntarily halt shipments of the gene therapy, but the company refused to do so and said it would continue making the treatment available to ambulatory patients. Explore courses from Top Institutes in Please select course: Select a Course Category Product Management Technology Degree Others Management Artificial Intelligence Public Policy MCA others PGDM healthcare Design Thinking Operations Management Finance Data Analytics Project Management MBA CXO Digital Marketing Leadership Data Science Data Science Skills you'll gain: Product Strategy & Competitive Advantage Tactics Product Development Processes & Market Orientations Product Analytics & Data-Driven Decision Making Agile Development, Design Thinking, & Product Leadership Duration: 40 Weeks IIM Kozhikode Professional Certificate in Product Management Starts on Jun 26, 2024 Get Details Skills you'll gain: Product Strategy & Roadmapping User-Centric Product Design Agile Product Development Market Analysis & Product Launch Duration: 24 Weeks Indian School of Business Professional Certificate in Product Management Starts on Jun 26, 2024 Get Details Skills you'll gain: Creating Effective Product Roadmap User Research & Translating it to Product Design Key Metrics via Product Analytics Hand-On Projects Using Cutting Edge Tools Duration: 12 Weeks Indian School of Business ISB Product Management Starts on May 14, 2024 Get Details by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trekking pants for mountain sports and adventure travel Trek Kit India Shop Now But Sarepta has now voluntarily and temporarily paused all shipments of the therapy, effective end of Tuesday. The company said the decision would allow it to respond to requests from the FDA and maintain a positive relationship with the agency. "Though Sarepta claims its pause in shipments was voluntary, we think the company moved preemptively - bracing for an inevitable FDA mandate to pull the drug," said H.C. Wainwright analyst Mitchell Kapoor. Shares of Sarepta fell 6.9% to $12.40 in early trading on Tuesday. Live Events "Sarepta's decision to comply was a capitulation after recognizing that the fight with the FDA was not winnable and that the agency would have strong-armed Sarepta into removing Elevidys with a formal demand," Kapoor added. Investor concerns regarding the use of the company's treatments have been heightened after the company on Friday disclosed that another patient who had received its experimental gene therapy died from acute liver failure , marking the third death this year. The company's shares have plummeted 89% so far this year. On Monday, Children's Hospital Los Angeles said it had paused usage of Elevidys in all patients with muscular dystrophy . The FDA's initial request had likely heightened the pressure on physicians to pause treatments, which could also have been a driving factor in Sarepta's decision, William Blair analyst Sami Corwin said.
Yahoo
06-07-2025
- Business
- Yahoo
H.C. Wainwright Maintains a Buy on Legend Biotech (LEGN) With a $75 Price Target
Legend Biotech Corporation (NASDAQ:LEGN) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 2, analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech Corporation (NASDAQ:LEGN) with a $75.00 price target. A laboratory with workers in masks and lab coats focused on analyzing cell therapies. The analyst highlighted the company's promising outlook, supported by its CARVYKTI. Another factor suggesting the treatment's favorable risk-benefit profile is the FDA approval of a supplemental BLA for CARVYKTI that eliminates the need for a risk evaluation and mitigation strategy. The analyst expects this factor, coupled with the updated monitoring requirements, to expedite the launch of CARVYKTI in the US market. In addition, the extensive experience of physicians with CARVYKTI, despite the recommendation by the European Medicines Agency to include warnings regarding potential immune-mediated enterocolitis, suggests that the product's benefits outweigh its risks. Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage company that develops, discovers, manufactures, and commercializes novel therapies for oncology and other indications. It develops advanced cell therapies across an elaborate range of technology platforms. The company operates in the US, China, and other geographical segments. While we acknowledge the potential of LEGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial
On May 27, analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) while keeping the price target at $45. The reiterated bullish sentiment comes after the company initiated the dosing of its OKRA-002 trial ahead of the schedule. A clinical researcher in a lab examining a new biopharmaceutical product. Kapoor noted the early start of dosing for OKRA-002 to be a significant milestone for the company. ORKA-002 is a novel monoclonal antibody targeting IL-17A and IL-17F for psoriasis; early start indicates the company's attention to clinical development timelines. Moreover, Kapoor believes that ORKA-001 and ORKA-002 are well-positioned to compete with existing treatments such as Bimzelx. Therefore, the analyst highlights the current valuation of Oruka Therapeutics, Inc. (NASDAQ:ORKA) does not reflect the potential of its lead products. Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics primarily for psoriasis and other inflammatory and immunology conditions. ORKA-001 and ORKA-002 are the company's lead products. While we acknowledge the potential of ORKA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ORKA and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None.
Yahoo
27-05-2025
- Business
- Yahoo
H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial
On May 27, analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) while keeping the price target at $45. The reiterated bullish sentiment comes after the company initiated the dosing of its OKRA-002 trial ahead of the schedule. A clinical researcher in a lab examining a new biopharmaceutical product. Kapoor noted the early start of dosing for OKRA-002 to be a significant milestone for the company. ORKA-002 is a novel monoclonal antibody targeting IL-17A and IL-17F for psoriasis; early start indicates the company's attention to clinical development timelines. Moreover, Kapoor believes that ORKA-001 and ORKA-002 are well-positioned to compete with existing treatments such as Bimzelx. Therefore, the analyst highlights the current valuation of Oruka Therapeutics, Inc. (NASDAQ:ORKA) does not reflect the potential of its lead products. Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics primarily for psoriasis and other inflammatory and immunology conditions. ORKA-001 and ORKA-002 are the company's lead products. While we acknowledge the potential of ORKA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ORKA and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Sign in to access your portfolio
